Thank you so much for attending this call. This is Peter Osbourne speaking, CEO of Midsona. As a top line summary, I would conclude that we took a step forward. Also, in the third quarter, we delivered organic sales growth for the second consecutive quarter. We significantly strengthen our margins and also our operating results. That said, we are on a journey, and the steps taken so far are really only the first steps in our long-term quest to reach our financial targets.
And before we delve into the numbers, I would just like to make you aware that there might be certain forward-looking statements in this presentation and that such statements are subject to risk and uncertainty.
So let's dive into quarter three.
I would say that overall we are reasonably happy with our progress in the quarter. Sales were slightly down due to currency effects, but we're still posting an organic sales growth of just below 3%. Looking at EBIT, before one-off items, we improved to 32 million, which should be compared to 18 million last year. Absolute EBIT increased from 9 million last year to 32 million Swedish kronor this year. So quite a good improvement. And if we look at the key components or ingredients of that, of course we're helped by the organic sales. We have good management of our product mix and also quite effective cost control. One of the key items is, of course, the gross margin. And we saw a good increase from 25.2% last year to 25.28% this year. And this is before items affecting comparability. And this was despite continued high raw material prices. Despite this, we have continued our complexity reduction project. What we are doing is relentlessly stopping low-margin products. We are keenly focused on discontinuing both low-profit product lines and private label and foodservice options, thereby considerably improving our margin profile. It's also worth noting that our leverage has come down significantly. Net debt in relation to EBITDA was at two times in quarter three, and that should be compared to four times last year. So we have effectively halved our leverage in one year. And this, to me and hopefully to you, clearly signals that we are a financially much more solid company. Clearly signals that we are financially a much more solid company. So as a key conclusion, I would say that we are taking steps forward also in quarter three. But still, there is a lot to improve. Let's dive into our different categories or segments. We did see slight organic growth; the organic category grew by 2%. I would say that market conditions are still somewhat challenging. And generally speaking, we see some stabilization in certain markets, but also some markets and channels are still quite depressed. So in that light, I think that we should be quite satisfied with an organic growth of 2%. Our expectation is that the market will gradually improve as we see lower inflation and interest rates coming down, and we think that this will restore consumer confidence and spending also in the organic category. I would also state that our market intelligence clearly shows that consumers want to spend on healthy and sustainable products, but they have been somewhat restrained by the economic downturn in the last couple of years. But as economic conditions improve, we think that market conditions for organic will also improve. And one of the brands that grew nicely was Davert in Germany. It was held by completely new customers, as well as new listings, that helped older customers. Helios continued to grow nicely in Norway, while we saw slight declines in the market as the market condition for organic foods was still somewhat restrained in both Sweden and Denmark. Private Label continues to be a major driver in the organic segment. Demand was very high, but we also faced some production constraints, especially in our German factories. And had it not been for those, sales could have been even higher. If we look at our conventional health food brands, we saw a decline, and this was completely due to us stepping out of some less profitable private label contracts and brand campaigns. On the positive side, Friggs continued to grow in the consumer health category. We saw very strong growth, 20% organic growth, and this was driven by a new distribution contract in Finland, but also very good performance for some of our key brands. Let's go into the divisions. All three divisions improved operating profit compared to last year. But it should be said that it's really the Nordic division which is the shining star. Um, it's flat sales, actually, as we continue to terminate some unprofitable contracts. But also, as mentioned before, we had weak market conditions for organic foods. Friggs continued to perform very well. Helios developed very nicely in Norway. Helios developed very nicely in Norway, and we did see good development for many of our consumer health brands in the Nordic region as well. So while we saw some ups and downs in sales, EBIT saw very strong development. We are selling a more profitable mix, as we have put more emphasis on our brands while simultaneously exiting low profitability private label contracts. Private label contracts and EBIT improved a very nice 35% to 66 million in the quarter. The North Division sales increased by 3%. And this was despite some supply challenges that we are putting a lot of effort into fixing now. We have installed extra shifts and are also working on production efficiency to better meet the expected high demand, not only in quarter four but also going forward in Germany. I would say that in Division North, the third quarter is a bit of a low season. We posted a loss of 3 million SEK in EBIT. It's better than the negative 7 million last year. But of course, it's not at a satisfactory level. We love them, so we will continue to work on strongly improving performance in Division Ascheberg. Also, in the division itself, we experience a bit of a low season in the third quarter; however, I would say that it's still an issue since a deficit of eight million is, of course, very significant and unacceptably low. We have initiated several projects aimed both at improving operations and boosting sales within the region. Gross margin and gross margin management are the key drivers behind our improved profit. And here is, of course, good to see that we are doing well in all three divisions, and it's pretty much the same factors in all the divisions that contribute to the better gross margin. It's efficient price management. We are step by step improving production efficiency, but it is still a long way to go. To be as effective as we want. We are substituting low-margin Private Label contracts with better-margin ones. We do discontinue low-margin full-service contracts, and we also focus some licensing agreements on our brands with higher margins. And it should also be said that in this mix, we have robust, stable raw material prices. We continue to drive innovation. This is very important for us in order to drive net sales and achieve organic growth. I will just show two quick examples. One is the new innovative spreads that we have launched under the brand name Davert in Germany. And we say that, generally speaking, we do see very high demand for our spreads. And we have recently expanded our production in this segment. Another example, which you can find on the next page, is Gainomax, the sports nutrition brand. And we have recently added three new tasty bars with a healthier profile, solid content, and no added sugar. For those of you following us, you have seen this before. Our strategy that was presented in the spring. It's really focused on increasing our profitability and strengthening our market position for the future. And we have three main pillars to do this. One is what we call an organic powerhouse. It's about strengthening our organic portfolio. Then we have the strategy to grow and expand our health brands, brands like Friggs and Gainomax that I've talked about earlier in the presentation.
And last but not least, to really step-change our internal efficiency and harmonization by driving efficiency across the total value chain, from sourcing to production. At the same time as we updated our strategy, we also updated our financial targets.
So this was done in spring. It's our aim to reach an organic sales growth of 3 to 5% per year. As I said earlier, we are posting the second quarter in a row with organic sales growth. It was 2.6%. We're still not up at the level where we want to be, but step by step, we should get there with a bit of 8%. And this we should achieve by 2027. Still, of course, there's quite some way to go. And this is really one of our main focus areas to step by step drive towards that target. We do take a decent step forward from 2% in quarter three, 2023 to 3.5% in quarter three this year. And last but not least, a gearing of net debt versus EBITDA of maximum 2.5 times. We are already below this, and as I said, this signals that we are now much more financially stable and can therefore be more aggressive in the future. Before I hand over to CFO Max Bokander, I would just like to give a brief summary. Our third quarter earnings show that we are on the right track. We can see that the continuous streamlining and coordination of the product range has had a clear impact on earnings, and we are continuing to work to create conditions for organic growth. And indeed, we achieved organic growth for the second quarter in a row. Now in quarter three.
The focus for the rest of 2024 and the upcoming year is, of course, to continue with the implementation of the strategy. 2025 is, of course, to continue with the implementation of the strategy. We are happy about the progress so far, but far from satisfied.
It is our ambition now to step by step move towards our financial targets. Max, please. Thank you, Peter. I will start with a short financial summary for the quarter, and the net sales declined by 0.4%, but clean from currency and structural effects, the sales grew by 2.6%. The gross margin continued to improve by 2.3 percentage points, and the EBIT increased by 77% compared to last year. The net result improved.